Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborating Sponsors:

Celgene Corporation

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgi...

Detailed Description

This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgi...

Eligibility Criteria

Inclusion

  • Histologically or cytologically confirmed SCCHN or poorly differentiated or undifferentiated cancer of the head and neck.
  • Measurable disease.
  • All primary sites are eligible excluding nasopharyngeal.
  • Surgically unresectable and/or N2b or greater nodal disease; Note: surgical unresectability will be defined as the combination of the treating surgeon's judgment of unresectability plus one of the following objective criteria:
  • Encasement of tumor or nodes to the carotid artery or ¾ encasement of the carotid artery.
  • Involvement of prevertebral musculature
  • Invasion of the bone of the skull base
  • Need for glossectomy or extensive glossal resection where functional outcome is considered unacceptable to surgeon or patient
  • Involvement of the cervical spine
  • Severe, unacceptable functional deficit that would result from any proposed definitive surgical resection.
  • ECOG performance status 0-1
  • Prior therapy:
  • Chemotherapy: No prior chemotherapy for the treatment of SCCHN.
  • Platinum chemotherapy: No previous history of carboplatin or cisplatin therapy.
  • Nab-paclitaxel: No previous treatment with nab-paclitaxel or another taxane.
  • Cetuximab: No previous treatment with cetuximab Or another epidermal growth factor receptor (EGFR) inhibitor.
  • Radiation therapy: No prior radiation to the head and neck region.
  • Age \> or = 18 years. Men and women are eligible for participation.
  • Must have acceptable organ and marrow function as defined below. Laboratory tests should be completed within 14 days prior to registration:
  • Absolute Neutrophil Count (ANC) \> or = 1,500/mm3
  • Platelets \> or = 100,000/mm3
  • Hemoglobin (Hgb) \> 9g/dL
  • Total bilirubin \< or = 1.5mg/dL
  • Albumin \> 2.5 g/dL
  • Aspartate aminotransferase (AST)/Alanine Aminotransferase (ALT) \< or = 2.5 times institutional upper limit of normal, alkaline phosphatase \< 2.5 x upper limit of normal, glomerular filtration rate (GFR) \> 30 mL/min (by standard Cockcroft and Gault formula or measured via 24 hour urine collection)
  • No pre-existing neuropathy greater than grade I
  • Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to day 1 of study treatment.
  • Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for three months after completing treatment. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care.
  • Patients must have the ability to understand and the willingness to sign a written informed consent document.
  • Patients must have a negative result for preformed immunoglobulin E (IgE) antibodies to galactose-alpha-1,3,-galactose.

Exclusion

  • Prior treatment with any of the study medications.
  • Prior radiation to any of the field required to treat the tumor.
  • Any metastatic disease.
  • The patient may have had a prior malignancy but must be disease-free for three years prior to study entry. A history of superficial non-melanoma skin cancer or in situ carcinoma of the cervix less than three years will be allowed.
  • Pregnant or lactating female
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, or psychiatric illness/social situations that would limit compliance with study requirements. Cardiac disease such as symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction will result in exclusion only if active within the past six months. Cardiac dysrhythmia will only result in exclusion if active and symptomatic (for example, rate-controlled atrial fibrillation will not result in exclusion).

Key Trial Info

Start Date :

February 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2019

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT01412229

Start Date

February 1 2012

End Date

December 1 2019

Last Update

November 23 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27599

2

Vanderbilt University

Nashville, Tennessee, United States, 37232

3

University of Washington

Seattle, Washington, United States, 98194